Role and mechanism of autophagy‐regulating factors in tumorigenesis and drug resistance

RM Usman, F Razzaq, A Akbar… - Asia‐Pacific Journal …, 2021 - Wiley Online Library
A hallmark feature of tumorigenesis is uncontrolled cell division. Autophagy is regulated by
more than 30 genes and it is one of several mechanisms by which cells maintain …

PUMA, a potent killer with or without p53

J Yu, L Zhang - Oncogene, 2008 - nature.com
PUMA (p53 upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2
family member and a critical mediator of p53-dependent and-independent apoptosis …

Transcription-independent p53 apoptosis: an alternative route to death

D Speidel - Trends in cell biology, 2010 - cell.com
Apoptosis induced by p53 is firmly established as a central mechanism of tumour
suppression. In addition to its complex functions as a nuclear transcription factor, p53 can …

Recent advances in the therapeutic perspectives of Nutlin-3

P Secchiero, R Bosco, C Celeghini… - Current pharmaceutical …, 2011 - ingentaconnect.com
Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-
genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. A series …

IL-4 enhances expression and function of surface IgM in CLL cells

MM Aguilar-Hernandez, MD Blunt… - Blood, The Journal …, 2016 - ashpublications.org
Kinase inhibitors targeting the B-cell receptor (BCR) are now prominent in the treatment of
chronic lymphocytic leukemia (CLL). We have focused here on interleukin 4 (IL-4), a …

[HTML][HTML] The cytoplasmic side of p53's oncosuppressive activities

A Comel, G Sorrentino, V Capaci, G Del Sal - FEBS letters, 2014 - Elsevier
The tumor suppressor p53 is a transcription factor that in response to a plethora of stress
stimuli activates a complex and context-dependent cellular response ultimately protecting …

Targeting p53 by small molecules in hematological malignancies

MN Saha, L Qiu, H Chang - Journal of hematology & oncology, 2013 - Springer
Abstract p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A
breakthrough in cancer research came from the discovery of the drugs which are capable of …

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

L Haronikova, O Bonczek, P Zatloukalova… - Cellular & molecular …, 2021 - Springer
Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the
cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the …

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

M Larrayoz, SJ Blakemore, RC Dobson, MD Blunt… - Leukemia, 2016 - nature.com
The pro-survival Bcl-2 family member Mcl-1 is expressed in chronic lymphocytic leukaemia
(CLL), with high expression correlated with progressive disease. The spliceosome inhibitor …

Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast

AN Sharp, AEP Heazell, D Baczyk, CE Dunk… - PloS one, 2014 - journals.plos.org
Background Preeclampsia (PE) is characterized by exaggerated apoptosis of the villous
trophoblast of placental villi. Since p53 is a critical regulator of apoptosis we hypothesized …